Format

Send to

Choose Destination
Vaccine. 2019 Mar 22;37(13):1775-1784. doi: 10.1016/j.vaccine.2019.02.030. Epub 2019 Feb 20.

Differential durability of immune responses to measles and mumps following MMR vaccination.

Author information

1
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: kennedy.rick@mayo.edu.
2
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
3
Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.
4
Division of Biomedical Statistics and Informatics, Department of Health Science Research, Mayo Clinic, Rochester, MN 55905, USA.

Abstract

The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.

KEYWORDS:

Antibodies; Cell-mediated immunity; Humoral immunity; MMR-II vaccine; Measles; Measles vaccine; Measles virus; Mumps; Mumps vaccine; Mumps virus; T cell ELISPOT

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center